Replies to post #41774 on Elite Pharmaceuticals Inc (ELTP)

[DR Ryan]

The last update I saw ECR was still saying "We're working as hard as we can to get it back on the market."

I think this was 2-3 months ago.

[Helotours]

Hike,

I received a reply from Davis Caskey about two weeks ago.

I will post it, in full - in a few minutes.

[Helotours]

Hike,

I just realized that the email is on my other computer at our main office and I have no way of accessing that information right now. However, I can try to relay the gist of the message from memory.

About two weeks ago, Mr. Davis Caskey (from ECR, VP, I believe) were involved in an email exchange about the future of the Lodrane ER drugs coming back to market. The bottom line is that the FDA (at the time) had not yet even responded to ECR's preliminary information filing regarding drug development procedures. Mr. Caskey indicated to me that although the FDA had sixty days to complete the response - they were running on almost 160 days, without any information/response.

According the Mr. Caskey, the debt crisis is creating uncertainties for them (and wondering if the FDA will receive funding to appropriately respond to drug applications). In light of the extremely long FDA response times that ECR is being presented with, Mr. Caskey indicated to me that ECR will be meeting early in 2013 to evaluate whether or not to proceed with the continued development of the Lodrane ER line. Citing a $2,000,000 initial fee, plus other costs and increased waiting times, Mr. Caskey believes that the development of the program will have to be re-evaluated from a cost perspective.

I will be glad to forward his email as soon as I get back to the main office. He has indicated to me a number of times that he does not mind my sharing email communication with other investors.

I hope everyone has a great day.